

New method for treatment or prevention of ocular diseases

A new method based on the inhibition of a key compound involved in pathologies that affect the retina, which can be used either to treat or prevent ocular diseases. Partners to further develop the technology and/or to establish commercial agreements along with technical cooperation are sought.

The Need

All the diseases affecting the retina are of great impact, because they lead to blindness or altered vision, and also they are generally linked with highly prevalent disorders, such as diabetes mellitus and tumours. The retinal pigment epithelium (RPE) is a cell layer just outside the neurosensory retina that protects, supports, and feeds it. Most of the treatments are implemented in advanced stages of the diseases, and they have many side effects and a high ratio of failures.

The Solution

The researchers have developed a new method for treating and/or preventing retinal diseases based on the inhibition of a protein involved in these pathologies through administration of an antibody that specifically binds to the related protein and blocks the interaction with its receptor sited in the retina. These antibodies prevent the disruption, or allow the restitution, of the disrupted retinal pigment epithelium (RPE), which is the first area of the retina to get degenerated.

Innovative Aspects


- ✓ In contrast with the currently available treatments, this method can be applied in very early stages of the retinal diseases.
- ✓ This method can also be used to prevent the appearance of retinal diseases because it targets the protein that is ultimately responsible for their etiology.

Stage of Development

Permeability and treatment assays were performed *in vitro* with human retinal cell lines.

Target Market

Pharma and biotech companies



Simulation of a retinal disease



The correlation of retinal diseases with highly prevalent disorders makes them of common presence in society, thus representing a challenge for the health institutions.

IP rights

PCT application

Portfolio of technologies

www.vhir.org/innovacio

We are looking for...

Partners to establish co-development or licensing agreements in order to further develop this technology.

Contact details

Innovation Unit

Vall d'Hebron Research Institute (VHIR)
Passeig Vall d'Hebron, 119 – 129
08035 – Barcelona
Tel. 934 893 000 (ext. 4844)
direccio.innovacio@vhir.org
www.vhir.org